Skip to main content
SpringerLink
Log in

CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

With the arrival of effective symptomatic treatments and the promise of drugs that may delay progression, we now need to identify Alzheimer’s disease (AD) at an early stage of the disease. To diagnose AD earlier and more accurately, attention has been directed toward peripheral biochemical markers. This article reviews promising potential cerebrospinal fluid (CSF) biomarkers for AD focussing on their role in clinical diagnosis. In particular, two biochemical markers, CSF total tau (t-tau) protein and the 42 amino acid form of β-amyloid (Aβ42), perform satisfactorily enough to achieve a role in the clinical diagnostic settings of patients with dementia together with the cumulative information from basic clinical work-up, genetic screening, and brain imaging. These CSF markers are particularly useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias. In order to discriminate AD from other primary dementia disorders, however, more accurate and specific markers are needed. Preliminary evidence strongly suggests that quantification of tau phosphorylated at specific sites in CSF improves early detection, differential diagnosis, and tracking of disease progression in AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mckhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. M. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34, 939–944.

    PubMed  CAS  Google Scholar 

  2. Tierney M. C., Fisher R. H., Lewis A. J., et al. (1988) The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer’s disease: a clinicopathologic study of 57 cases. Neurology 38, 359–364.

    PubMed  CAS  Google Scholar 

  3. Jellinger K. A. (1996) Diagnostic accuracy of Alzheimer’s disease: a clinicopathological study. Acta Neuropathol. 91, 219–220.

    Article  PubMed  CAS  Google Scholar 

  4. Galasko D., Hansen L. A., Katzman R., Wiederholt W., Masliah E., Terry R., et al. (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch. Neurol. 51, 888–895.

    PubMed  CAS  Google Scholar 

  5. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. (1998) Consensus report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease.” Neurobiol. Aging 19, 109–116.

    Article  Google Scholar 

  6. Goedert M. (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. TINS 16, 460–465.

    PubMed  CAS  Google Scholar 

  7. Vandermeeren M., Mercken M., Vanmechelen E., Six J., Van de Voorde A., Martin J. J., Cras P. (1993) Detection of τ proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61, 1828–1834.

    Article  PubMed  CAS  Google Scholar 

  8. Blennow K., Wallin A., Ågren H., Spenger C., Siegfried J., Vanmechelen E. (1995) Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol. Chem. Neuropathol. 26, 231–245.

    PubMed  CAS  Google Scholar 

  9. Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45, 788–793.

    PubMed  CAS  Google Scholar 

  10. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., et al. (1999) Improved discrimination of AD patients using beta-amyloid(1–42) and tau levels in CSF. Neurology 52, 1555–1562.

    PubMed  CAS  Google Scholar 

  11. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., et al. (1998) Cernrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community-based follow-up study. J. Neurol. Neurosurg. Psychiatry 64, 298–305.

    PubMed  CAS  Google Scholar 

  12. Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., et al. (1998) Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer’s disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20, 227–235.

    PubMed  CAS  Google Scholar 

  13. Skoog I., Vanmechelen E., Andreasson L. A., Palmertz B., Davidsson P., Hesse C., and Blennow K. (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4, 433–442.

    Article  PubMed  CAS  Google Scholar 

  14. Arai H., Satoh-Nakagawa T., Higuchi M., Morikawa Y., Miura M., Kawakami H., et al. (1998) No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci. Lett. 256, 174–176.

    Article  PubMed  CAS  Google Scholar 

  15. Mecocci P., Cherubini A., Bregnocchi M., Chionne F., Cecchetti R., Lowenthal D. T., and Senin U. (1998) Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease? Alzheimer Dis. Assoc. Disord. 12, 211–214.

    Article  PubMed  CAS  Google Scholar 

  16. Arai H., Higuchi S., and Sasaki H. (1997) Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer’s disease. Gerontology 43(Suppl. 1), 2–10.

    Article  PubMed  CAS  Google Scholar 

  17. Green A. J., Harvey R. J., Thompson E. J., and Rossor M. N. (1999) Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer’s disease. Neurosci. Lett. 259, 133–135.

    Article  PubMed  CAS  Google Scholar 

  18. Molina L., Touchon J., Herpe M., Lefranc D., Duplan L., Cristol J. P., et al. (1999) Tau and apo E in CSF: potential aid for discriminating Alzheimer’s disease from other dementias. Neuroreport 10, 3491–3495.

    Article  PubMed  CAS  Google Scholar 

  19. Arai H., Morikawa Y., Higuchi M., Matsui T., Clark C. M., Miura M., et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem. Biophys. Res. Comm. 236, 262–264.

    Article  PubMed  CAS  Google Scholar 

  20. Higuchi M., Tashiro M., Arai H., Okamura N., Hara S., Higuchi S., et al. (2000) Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp. Neurol. 162, 247–256.

    Article  PubMed  CAS  Google Scholar 

  21. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., et al. (1995) Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 38, 643–648.

    Article  PubMed  CAS  Google Scholar 

  22. Sjögren M., Minthon L., Davidsson P., Granérus A. K., Clarberg A., Vanderstichele H., et al. (2000) CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107, 563–579.

    Article  PubMed  Google Scholar 

  23. Kanemaru K., Kameda N., and Yamanouchi H. (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54, 1875–1876.

    PubMed  CAS  Google Scholar 

  24. Kudo T., Mima T., Hashimoto R., Nakao K., Morihara T., Tanimukai H., et al. (2000) Tau protein is a potential biological marker for normal pressure hydrocephalus. Psych. Clin. Neurosci. 54, 199–202.

    Article  CAS  Google Scholar 

  25. Mitani K., Furiya Y., Uchihara T., Ishii K., Yamanouchi H., Mizusawa H., and Mori H. (1998) Increased CSF tau protein in corticobasal degeneration. J. Neurol. 245, 44–46.

    Article  PubMed  CAS  Google Scholar 

  26. Morikawa Y., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., et al. (1999) Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin. Exp. Res. 23, 575–577.

    PubMed  CAS  Google Scholar 

  27. Urakami K., Mori M., Wada K., Kowa H., Takeshima T., Arai H., et al. (1999) A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci. Lett. 259, 127–129.

    Article  PubMed  CAS  Google Scholar 

  28. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., and Blennow K. (2000) Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischaemic stroke. J. Alzheimer Dis. 2, 199–206.

    CAS  Google Scholar 

  29. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., et al. (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210–212.

    Article  PubMed  CAS  Google Scholar 

  30. Van Everbroeck B., Green A. J. E., Phals P., Martins J. J., and Cras P. (1999) Decreased levels of amyloid β 1–42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J. Alzheimer Dis. 1, 419–424.

    Google Scholar 

  31. Emery V. O. and Oxman T. E. (1992) Update on the dementia spectrum of depression. Am. J. Psychiatry 149, 305–317.

    PubMed  CAS  Google Scholar 

  32. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., et al. (1999) Sensitivity, specificity and stability of CSF t-tau in AD in a community-based patient sample. Neurology 53, 1488–1494.

    PubMed  CAS  Google Scholar 

  33. Buerger nee Buch K., Padberg F., Nolde T., Teipel S. J., Stubner S., Haslinger A., et al. (1999) Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer’s disease compared with controls. Neurosci. Lett. 277, 21–24.

    Article  Google Scholar 

  34. Buerger K., Zinkowski R., Teipel S. J., Tapiola T., Arai H., Blennow K., et al. CSF tau protein phosphorylated arthreonine 231 in the differential diagnosis of Alzheimer’s disease. Submitted, 2001.

  35. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. (2001) Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci. Lett. 297, 187–190.

    Article  PubMed  CAS  Google Scholar 

  36. Hampel H., Buerger K., Kohnken R., Teipel S. J., Zinkowski R., Moeller H. J., et al. (2001) Tracking of Alzheimer’s disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49, 545–546.

    Article  PubMed  CAS  Google Scholar 

  37. Jensen M., Schroder J., Blomberg M., Engvall B., Pantel J., Ida N., et al. (1999) Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression. Ann. Neurol. 45, 504–511.

    Article  PubMed  CAS  Google Scholar 

  38. Andreasen N., Hesse C., Davidsson P., Wallin A., Minthon L., Winblad B., et al. (1999) Cerebrospinal fluid β-amyloid(1-42) in Alzheimer’s disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673–680.

    Article  PubMed  CAS  Google Scholar 

  39. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. (2001) Evaluation of CSF t-tau and CSF-Aβ42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch. Neurol. 58, 373–379.

    Article  PubMed  CAS  Google Scholar 

  40. Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P., et al. (2000) Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099–1102.

    PubMed  CAS  Google Scholar 

  41. Sjögren M., Gisslén M., Vanmechelen E., and Blennow K. (2001) Low cerebrosinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314, 33–36.

    Article  PubMed  Google Scholar 

  42. Folstein M., Folstein S., and McHugh P. (1975) “Mini-Mental State” A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198.

    Article  PubMed  CAS  Google Scholar 

  43. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., and Kokmen E. (1999) Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303–308.

    Article  PubMed  CAS  Google Scholar 

  44. Arai H., Nakagawa T., Kosaka Y., Higuchi M., Matsui T., Okamura N., et al. (1997) Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired patients. Alzheimer’s Res. 3, 211–213.

    Google Scholar 

  45. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Longitudinal studies of cerebrospinal fluid biochemistry in patients with mild cognitive impairment. Submitted, 2001.

  46. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., et al. (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166, 201–203.

    Article  PubMed  CAS  Google Scholar 

  47. Blennow K., Wallin A., and Häger O. (1993) Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88, 221–223.

    Article  PubMed  CAS  Google Scholar 

  48. Kosunen O., Soininen H., Paljärvi L., Heinonen O., Talasniemi S., and Riekkinen P. J., Sr. (1996) Diagnostic accuracy of Alzheimer’s disease: a neuropathological study. Acta Neuropathol. 91, 185–193.

    Article  PubMed  CAS  Google Scholar 

  49. Tomlinson B. E. and Henderson G. (1976) Some quantitative cerebral findings in normal and emented old people, in Neurobiology of Aging (Terry R. D. and Gershon S., eds.), Raven Press, New York, NY, pp. 183–204.

    Google Scholar 

  50. Davies L., Wolska B., Hilbich C., et al. (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer’s disease. Neurology 38, 1688–1693.

    PubMed  CAS  Google Scholar 

  51. Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann. Neurol. 45, 358–368.

    Article  PubMed  CAS  Google Scholar 

  52. Kahle P. J., Jakowec M., Teipel S. J., Hampel H., Petzinger G. M., Di Monte D. A., et al. (2000) Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF. Neurology 54, 1498–1504.

    PubMed  CAS  Google Scholar 

  53. Hampel H., Teipel S. J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M. J., et al. (1999) Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 823, 104–112.

    Article  PubMed  CAS  Google Scholar 

  54. Jensen M., Basun H., and Lannfelt L. (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci. Lett. 186, 189–191.

    Article  PubMed  CAS  Google Scholar 

  55. Riemenschneider M., Buch K., Schmolke M., Kurz A., and Guder W. G. (1996) Cerebrospinal protein tau is elevated in early Alzheimer’s disease. Neurosci. Lett. 212, 209–211.

    Article  PubMed  CAS  Google Scholar 

  56. Rösler N., Wichart I., and Jellinger K. A. (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 60, 237–238.

    PubMed  Google Scholar 

  57. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta 1-40, and A beta 1-42(43) in Alzheimer’s disease: a study in Japan. Ann. Neurol. 44, 17–26.

    Article  PubMed  CAS  Google Scholar 

  58. Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., and Guder W. (1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12, 372–377.

    PubMed  CAS  Google Scholar 

  59. Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P Sr., and Soininen H. (1998) CSF tau is related to apolipoprotein E genotype in early Alzheimer’s disease. Neurology 50, 169–174.

    PubMed  CAS  Google Scholar 

  60. Vanderstichele H., Blennow K., D’Heuvaert N. D., Buyse M. A., Wallin A., Andreasen N., et al. (1998) Development of a specific diagnostic test for measurement of β-amyloid(1-42) in CSF in Progress in Alzheimer’s and Parkinson’s Diseases (Fisher A., Hanin I., and Yoshida M., eds.), Plenum Press, New York, NY, pp. 773–778.

    Google Scholar 

  61. Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J. M., et al. (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer’s disease. Neurosci. Lett. 270, 91–94.

    Article  PubMed  CAS  Google Scholar 

  62. Sjögren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelsö C., et al. Both total and hyperphosphorylated tau are increased in Alzeimer’s disease. J. Neurol. Neurosurg. Psychiatry 70, 624–630.

  63. Munroe W. A., Southwick P. C., Chang L., Scharre D. W., Echols C. L. Jr., Fu P. C., Whaley J. M., Wolfert R. L. (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. Ann. Clin. Lab. Sci. 25, 207–217.

    PubMed  CAS  Google Scholar 

  64. Galasko D., Clark C., Chang L., Miller B., Green R. C., Motter R., Seubert P. (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 48, 632–635.

    PubMed  CAS  Google Scholar 

  65. Galasko D., Chang L., Motter R., Clark C. M., Kaye J., Knopman D., et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55, 937–945.

    Article  PubMed  CAS  Google Scholar 

  66. Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., et al. (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci. Lett. 186, 181–183.

    Article  PubMed  CAS  Google Scholar 

  67. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 287, 187–190.

    Article  PubMed  CAS  Google Scholar 

  68. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van der Perre B., Sjögren M., et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49–52.

    Article  PubMed  CAS  Google Scholar 

  69. Riemenschneider M., Schmolke M., Lautenschlager N., Guder W. G., Vanderstichele H., Vanmechelen E., and Kurz A. (2000) Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284, 85–88.

    Article  PubMed  CAS  Google Scholar 

  70. Tamaoka A., Sawamura N., Fukushima T., Shoji S., Matsubara E., Shoji M., et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Sci. 148, 41–45.

    Article  PubMed  CAS  Google Scholar 

  71. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., et al. (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 271, 22,908–22,914.

    CAS  Google Scholar 

  72. Mehta P.D., Pirttilä T., Mehta S. P., Sersen E. A., Aisen P. S., and Wisniewski H. M. (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57, 100–105.

    Article  PubMed  CAS  Google Scholar 

  73. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., and Blennow K. (1999c) CSF t-tau and CSF-Aβ42 as predictors of development of Alzheimer’s disease in patients with mild cognitive impairment. Neurosci. Lett. 273, 5–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Neuroscience, Unit of Neurochemistry, University of Göteborg, Sweden

    Kaj Blennow

  2. The Medical Research Council (MRC), Sweden

    Kaj Blennow

  3. Innogenetics, Ghent, Belgium

    Eugeen Vanmechelen

  4. Dementia and Neuroimaging Research Section and Memory Clinic, Department of Psychiatry, Ludwig-Maximilian University, Munich, Germany

    Harald Hampel

Authors
  1. Kaj Blennow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugeen Vanmechelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harald Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaj Blennow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blennow, K., Vanmechelen, E. & Hampel, H. CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol 24, 87–97 (2001). https://doi.org/10.1385/MN:24:1-3:087

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/MN:24:1-3:087

Index Entries

Search

Navigation